Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)
NCT ID: NCT01138618
Last Updated: 2011-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
85 participants
OBSERVATIONAL
2010-04-30
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CHEMPAQ-venous-CHEMPAQ-venous
The two arms only differ in order of kind of blood samples.
Venous blod sample
Regular venous blood sample withdrawn from the laboratory
CHEMPAQ
Capillary blood sample analyzed by CHEMPAQ
Venous-CHEMPAQ-Venous-CHEMPAQ
The two arms only differ in order of kind of blood samples.
Venous blod sample
Regular venous blood sample withdrawn from the laboratory
CHEMPAQ
Capillary blood sample analyzed by CHEMPAQ
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Venous blod sample
Regular venous blood sample withdrawn from the laboratory
CHEMPAQ
Capillary blood sample analyzed by CHEMPAQ
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Compliant with blood monitoring
* Willing to give informed consent
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aalborg Psychiatric Hospital
OTHER
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jimmi Nielsen, MD
Role: PRINCIPAL_INVESTIGATOR
Aalborg Psychiatric Hospital, Aarhus University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Psychiatric Center Roskilde
Greve, Greve, Denmark
Aalborg Psychiatric Hospital
Aalborg, , Denmark
Psychiatric Center Aarhus
Aarhus, , Denmark
Psychiatric Center Copenhagen
Copenhagen, , Denmark
Psychiatric Centre Esbjerg
Esbjerg, , Denmark
Psychiatric Center Odense
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988 Sep;45(9):789-96. doi: 10.1001/archpsyc.1988.01800330013001.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1.5 - 01 MARCH2010
Identifier Type: -
Identifier Source: org_study_id